{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:56:57Z","timestamp":1780538217993,"version":"3.54.1"},"reference-count":6,"publisher":"S. Karger AG","issue":"11","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> The aim of this study was to test for differences in overall (OS) and progression-free survival (PFS) rates and toxicity in first-line immune checkpoint inhibition (IO) combination therapy in metastatic renal-cell carcinoma (mRCC) patients. <b><i>Methods:<\/i><\/b> Between November 2017 and April 2021, 104 patients with histologically confirmed mRCC from 6 tertiary referral centers with either IO + IO (nivolumab + ipilimumab, <i>n<\/i> = 68) or IO + tyrosine kinase inhibitor (TKI) (pembrolizumab + axitinib, <i>n<\/i> = 36) were included. Kaplan-Meier and Cox regression analyses tested for OS and PFS differences. <b><i>Results:<\/i><\/b> Of 104 mRCC patients, 68 received IO + IO (65.4%) and 36 IO + TKI (34.6%) therapy, respectively. Median age was 67 years (interquartile range: 57\u201370.3). Patients receiving IO + TKI were less likely to be poor risk according to the International Metastatic Renal-Cell Carcinoma Database Consortium score (16.7 vs. 30.9%) and presented with lower T-stage, compared to IO + IO treated patients. Median PFS was 9.8 months (CI: 5.3\u201317.6) versus 12.3 months (CI: 7.7 \u2013 not reached) for IO + IO versus IO + TKI treatment, respectively (<i>p<\/i> = 0.22). Median OS was not reached, survival rates at 12 months being 73.9 versus 90.0% for IO + IO versus IO + TKI patients (<i>p<\/i> = 0.089). In subgroup analyses of elderly patients (\u226570 years, <i>n<\/i> = 38), IO + TKI treatment resulted in better OS rates at 12 months compared to IO + IO (91.0 vs. 57.0%; <i>p<\/i> = 0.042). <b><i>Conclusion:<\/i><\/b> IO + IO and IO + TKI as first-line therapies in mRCC patients were both comparable as for the oncological outcome and toxicity. <\/jats:p>","DOI":"10.1159\/000521661","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:00:46Z","timestamp":1644876046000},"page":"1150-1157","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort"],"prefix":"10.1159","volume":"106","author":[{"given":"Benedikt","family":"Hoeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-0560","authenticated-orcid":false,"given":"Philipp","family":"Schmucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-0586","authenticated-orcid":false,"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-6588","authenticated-orcid":false,"given":"Philip","family":"Zeuschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Ellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-7171","authenticated-orcid":false,"given":"Julia","family":"Heinzelbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-8824","authenticated-orcid":false,"given":"Michael","family":"H\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Strau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-458X","authenticated-orcid":false,"given":"Angelika","family":"Mattigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0282-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000503870"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2017.10.002"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000499089"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02555.x"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:42:50Z","timestamp":1745422970000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000521661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":6,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,9]]},"published-print":{"date-parts":[[2022,11,14]]}},"URL":"https:\/\/doi.org\/10.1159\/000521661","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.19168355","asserted-by":"subject"}]},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}